Asep Inc. Receives Grant from NanoMedicines Innovation Network (NMIN), Funded by the Government of Canada
The New Grant Will Support Important Pre-clinical Studies
VANCOUVER, BC, June 23, 2023 /PRNewswire/ – Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce, along with their academic partners at the University of British Columbia (UBC), that they have been awarded a grant from the NanoMedicines Innovation Network (NMIN) to investigate further and identify an optimal nanoparticle-peptide solution with the specific goal of treating chronic sinus infections caused by biofilms. The Government of Canada funds NMIN through the Networks of Centres of Excellence (NCE) Program. To date, the Company and its subsidiaries have received over USD $20 million in non-dilutive grant funding from organizations such as the Bill and Melinda Gates Foundation, Genome Canada and UBC. The Company, through its pre-clinical partner, iFyber LLC, has also received funding from the US Army for its novel antibiofilm peptide technology.
Related news for (SEPSF)
- Asep Medical Featured in National Documentary
- Asep Medical Holdings Inc. to Hold Significant Investor Information Webinar this Friday, March 22, 2024, at 4 pm EST
- Asep Medical Confirms the Use of AI – Enables Improved Treatments for Common Biofilm Infections and Rapid Sepsis Diagnostics
- Asep Medical’s Sepsis Diagnostic Technology Can Provide Improved Odds for Pediatric Appendicitis
- ASEP INC. ANNOUNCES CLOSING OF DEBT SETTLEMENT